라미부딘 치료 후 라미부딘 내성을 보이지 않는 환자에서 엔테카비어 효과 = Effect of Entecavir in Patients Who Lack Lamivudine Resistance after Lamivudine Treatment for Chronic Hepatitis B

다국어 초록 (Multilingual Abstract)

Background/Aims: The effect of entecavir (ETV) in treatment-naive chronic hepatitis B (CHB) is well established. This study aimed to assess the efficacy of ETV treatment at 0.5 mg/day in ETV-switch and ETV-retreatment groups of CHB patients without lamivudine (LMV)-resistance from LMV monotherapy. Methods: Study subjects included 350 CHB patients who had been treated with 0.5 mg/day of ETV for at least 6 months. Patients were divided into two groups: an LMV-naive group (n = 263) and an LMV-experienced group (n = 87). The LMV-experienced group was further subdivided into an ETV-switch group (n = 43) and an ETV-retreatment group (n = 44) defined by the period between stopping LMV and restarting ETV. Results: There were no significant differences in mean age, sex ratio, prevalence of liver cirrhosis and hepatitis B e antigen (HBeAg) positivity between the LMV-naive and -experienced groups. However, the LMV-naive group had higher aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels and a shorter ETV treatment duration than the LMV-experienced group. There were also distributional differences in the hepatitis B virus (HBV) DNA levels of LMV-naive and -experienced patients prior to ETV treatment. After ETV treatment, there were no significant differences between the two groups in the rates of undetectable HBV DNA at 6, 12 and 18 months; HBeAg loss and seroconversion; normalization of ALT; virologic breakthrough; and ETV-genotypic resistance. Lastly, the effect of ETV did not differ between the ETV-switch and -retreatment groups. Conclusions: The effect of ETV in the LMV-experienced group without LMV-resistance did not differ from that in the LMV-naive group. Furthermore, there was no difference in the effect of ETV between the ETV-switch and -retreatment groups. (Korean J Med 2013;84:810-817)

참고문헌 (Reference)

1 명형준, "만성 B형간염 환자에 대한 초치료제로서 엔테카비어의 항바이러스 효과와 그 예측인자" 대한간학회 16 (16): 57-65, 2010

2 신정우, "만성 B형 간염 치료" 대한내과학회 77 (77): 265-274, 2009

3 Tenney DJ, "Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present" 51 : 902-911, 2007

4 Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level" 295 : 65-73, 2006

5 Lok AS, "Long-term safety of lamivudine treatment in patients with chronic hepatitis B" 125 : 1714-1722, 2003

6 Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy" 49 : 1503-1514, 2009

7 Ide T, "Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy" 4 : 594-600, 2010

8 Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B" 354 : 1011-1020, 2006

9 Suzuki F, "Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients" 25 : 892-898, 2010

10 Levine S, "Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro" 46 : 2525-2532, 2002

11 Baldick CJ, "Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance" 47 : 1473-1482, 2008

12 Tenney DJ, "Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine" 48 : 3498-3507, 2004

13 Reijnders JG, "Antiviral effect of entecavir in chronic hepatitis B : influence of prior exposure to nucleos(t)ide analogues" 52 : 493-500, 2010

14 Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B" 354 : 1001-1010, 2006